$4.09
-0.27-6.19%
Last update: Nov 5, 4:06 PM
Taysha Gene Therapies Inc (TSHA) Stock Price, Quote, News & History
TSHANASDAQ
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
You can purchase shares of Taysha Gene Therapies (NASDAQ:TSHA) through any online brokerage.
Other companies in Taysha Gene Therapies’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Taysha Gene Therapies has a consensus price target of $11.13.
The stock price for Taysha Gene Therapies (NASDAQ: TSHA) is $4.12 last updated November 5, 2026 at 4:06 PM EST.
There are no upcoming dividends for Taysha Gene Therapies.
Taysha Gene Therapies does not have any upcoming earnings scheduled.
There is no upcoming split for Taysha Gene Therapies.
Taysha Gene Therapies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in...
